MK-886
| Names | |
|---|---|
| Preferred IUPAC name
3-{3-(tert-Butylsulfanyl)-1-[(4-chlorophenyl)methyl]-5-(propan-2-yl)-1H-indol-2-yl}-2,2-dimethylpropanoic acid | |
| Other names
L-663536 | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| MeSH | L+663536 |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C27H34ClNO2S | |
| Molar mass | 472.083 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
MK-886, or L-663536, is a leukotriene antagonist. It may perform this by blocking the 5-lipoxygenase activating protein (FLAP), thus inhibiting 5-lipoxygenase (5-LOX), and may help in treating atherosclerosis.
MK-886 is a synthesized chemical compound known for its role in inhibiting the 5-lipoxygenase-activating protein (FLAP). Key part in leukotriene biosynthesis. It has potential therapeutic applications in different types of cancer when paired up with other synthetically made chemical compounds. This includes the cancer cells doing apoptosis and suppress tumor cell growth independent from leukotriene inhibition with some cases.